Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 4,560 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: assessment only control Clear all

Conditions: Physical Inactivity
Interventions: ACtive Children Enhance LEaRning and AttenTION (ACCELERATION); Behavioral
Lead sponsor: University of Houston; Other
Eligibility: 8 Years to 11 Years
Enrollment: 257 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Reproductive Sterilization
Interventions: Adiana Transcervical Sterilization System; Device
Lead sponsor: Hologic, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 770 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2013
U.S. locations: 14
States / cities: Phoenix, Arizona • Roseville, California • San Rafael, California + 11 more

Conditions: Malaria
Interventions: D/ChAd63-CA, D/ChAd63-CAT, Infectivity Control (IC) Group; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Bethesda, Maryland • Silver Spring, Maryland

Conditions: Ankle Sprain
Interventions: High velocity, low amplitude stretch, Slow, mobilization stretch, Passive Positioning; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diffuse Large B-cell Lymphoma
Interventions: CC-5013 (lenalidomide), dexamethasone; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Glendale, Arizona • Beverly Hills, California • Miami, Florida + 15 more

Conditions: Early-Onset Alzheimer Disease
Interventions: ALN-APP, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 2
States / cities: La Jolla, California • Indianapolis, Indiana

Conditions: Healthy Volunteer
Interventions: AZD7325; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Kidney Failure
Interventions: rhC1INH, Saline Solution; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Cystic Fibrosis
Interventions: VX-661, Ivacaftor, Placebo matched to VX-661, Placebo matched to ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Oakland, California • Boise, Idaho + 16 more

Conditions: Diabetic Macular Edema
Interventions: Bevacizumab, dexamethasone intravitreal implant; Drug
Lead sponsor: Maturi, Raj K., M.D., P.C.; Individual
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy
Interventions: Control digestible carbohydrate, Test resistant starch type 4; Other
Lead sponsor: Cargill; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Meibomian Gland Dysfunction (Disorder)
Interventions: TearCare®; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 29 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Type 1 Diabetes, Hypoglycemia
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Migraine
Interventions: TEZAMPANEL; Drug
Lead sponsor: TorreyPines Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: tarenflurbil, adjuvant therapy; Drug · Procedure
Lead sponsor: Myrexis Inc.; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 58
States / cities: Homewood, Alabama • Anchorage, Alaska • Fresno, California + 49 more

Conditions: Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
Interventions: Pegfilgrastim, Placebo, Bevacizumab, Standard Chemotherapy; Drug · Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 72
States / cities: Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more

Conditions: Stress, Psychological, Post-Traumatic Stress Disorder, Major Injury
Interventions: DEF-only, DEF + COPE; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Up to 5 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: End-Stage Renal Disease
Interventions: Rivaroxaban 15 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Healthy Participants
Interventions: E6742, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Tobacco Use Disorder, Smoking
Interventions: Ariva Silver Wintergreen, Ariva Wintergreen; Other
Lead sponsor: Star Scientific, Inc; Industry
Eligibility: 23 Years to 72 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Martinsburg, West Virginia

Conditions: Tuberculosis
Interventions: MK-7762 (TBD09), Placebo; Drug · Other
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 19 Years to 55 Years
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: COPD, Dyspnea
Interventions: Vitabreath Device, Pursed Lip Breathing; Device · Other
Lead sponsor: Philips Respironics; Industry
Eligibility: 40 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Youngstown, Ohio • Jefferson Hills, Pennsylvania

Conditions: HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: CARE+; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Seattle, Washington

Search by objective public record fields.

ACtive Children Enhance LEaRning and AttenTION: A Randomized Controlled Trial (RCT)

Safety & Efficacy Study of the Adiana System for Women Who Desire Permanent Birth Control (Sterilization)

Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults

Ankle Sprains and Corticospinal Excitability

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

AZD7325 Multiple Ascending Dose Study

RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema

A Randomized, Controlled, Crossover Study to Assess the Glucose and Insulin Excursions of a Test Fiber

TearCare in Young Adults

Investigation Into the Effects Upon Brain Response to Change in Circulating Glucose Levels in Diabetes Mellitus

Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine

R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Intervention to Reduce Stress in 0-5 Year Olds With Burns

A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients

Computer Assisted Rx Education for HIV-Positives: CARE+